文献速递主动脉疾病

影像学量化的肌少症与传统心血管风险评估对腹主动脉瘤腔内修复术后长期死亡率的预测

Radiographically quantified sarcopenia and traditional cardiovascular risk assessment in predicting long-term mortality after endovascular aortic repair.
PubMed 文献 · J Vasc Surg · 2022-03-31

该回顾性研究纳入480例标准EVAR治疗完整肾下腹主动脉瘤患者,术前CT测量L3水平腰大肌面积(PMA),结合ASA评分分为高、中、低危三组。多因素分析显示年龄、ASA评分、PMA、慢性肾病和最大瘤囊直径是长期死亡的独立预测因素。高危及中危组长期死亡率显著高于低危组,联合ASA与PMA可作为简单风险分层工具。

要点

  • 高危及中危组1年死亡率分别为18%±5%和5%±2%,低危组为5%±2%(P<.01)。
  • 高危及中危组5年死亡率分别为60%±6%和36%±3%,低危组为23%±4%(P<.01)。
  • 年龄、ASA评分、PMA、慢性肾病和最大瘤囊直径是长期死亡的独立预测因素。

核心结论

  • ASA评分和PMA均是择期EVAR术后死亡率增加的强预测因素,两者联合可作为简单风险分层工具,识别动脉瘤修复或EVAR术后强化长期监测可能不必要的患者。

研究设计与样本

  • 回顾性研究纳入480例因完整肾下腹主动脉瘤接受标准EVAR治疗的患者,收集术前特征、合并症、动脉瘤尺寸等风险因素,术前CT测量L3水平腰大肌面积(PMA),根据ASA评分和PMA将患者分为高、中、低危三组。

主要发现

  • 高危组、中危组和低危组年龄分别为77±7岁、76±6岁和74±8岁(P<.01)。
  • 高危组冠状动脉疾病、肺部疾病和慢性肾病患病率更高。
  • 三组间30天或90天死亡率无差异。
  • 长期死亡的独立预测因素为年龄、ASA评分、PMA、慢性肾病和最大瘤囊直径。
  • 低危组、中危组和高危组1年死亡率分别为5%±2%、5%±2%和18%±5%(P<.01);5年死亡率分别为23%±4%、36%±3%和60%±6%(P<.01)。

关键数值与推荐

  • 肌少症定义为男性PMA<8.0 cm2、女性PMA<5.5 cm2。
  • 高危组:存在肌少症且ASA评分为4;中危组:存在肌少症或ASA评分为4;低危组:无肌少症且ASA评分小于4。

临床怎么用

  • 作者认为ASA评分和PMA联合可用作简单风险分层工具,识别动脉瘤修复或EVAR术后强化长期监测可能不必要的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluated radiographically quantified sarcopenia and the patient's comorbidity burden based on traditional cardiovascular risk assessment as potential predictors of long-term mortality after endovascular aortic repair (EVAR). METHODS: The study included 480 patients treated with standard EVAR for intact infrarenal abdominal aortic aneurysms. Patient characteristics, comorbidities, aneurysm dimensions, and other preoperative risk factors were collected retrospectively. Preoperative computed tomography was used to measure psoas muscle area (PMA) at the L3 level. Patients were divided into three groups based on American Society of Anesthesiologists (ASA) score and PMA. In the high-risk group, patients had sarcopenia (PMA <8.0 cm2 for males and <5.5 cm2 for females) and an ASA score of 4. In the medium-risk group, patients had either sarcopenia or an ASA score of 4. Patients in the low-risk group had no sarcopenia and the ASA score was less than 4. Risk factors for long-term mortality were determined using multivariable analysis. Kaplan-Meier survival estimates were calculated for all-cause mortality. RESULTS: Patients in the high- and medium-risk groups were older than those in the low-risk group (77 ± 7, 76 ± 6, and 74 ± 8 years, respectively, P < .01). Patients in the high-risk group had higher prevalence of coronary artery disease, pulmonary disease, and chronic kidney disease. There were no differences in 30-day or 90-day mortality between the groups. The independent predictors of long-term mortality were age, ASA score, PMA, chronic kidney disease, and maximum aneurysm sac diameter. The estimated 1-year mortality rates were 5% ± 2% for the low-risk, 5% ± 2% for the medium-risk, and 18% ± 5% for the high-risk group (P < .01). Five-year mortality estimates were 23% ± 4%, 36% ± 3%, and 60% ± 6%, respectively (P < .01). The mean follow-up time was 5.0 ± 2.8 years. CONCLUSIONS: Both ASA and PMA were strong predictors of increased mortality after elective EVAR. The combination of these two can be used as a simple risk stratification tool to identify patients in whom aneurysm repair or the intensive long-term surveillance after EVAR may be unwarranted.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Paajanen P, Lindström I, Oksala N, et al. Radiographically quantified sarcopenia and traditional cardiovascular risk assessment in predicting long-term mortality after endovascular aortic repair. J Vasc Surg. 2022. PMID: 35367563. doi:10.1016/j.jvs.2022.03.859

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。